在药物安全监察(pharmacovigillance)工作中,由于不良事件(Adverse Events,AE)漏报的数量不清楚,往往无法了解到底有多少病人真正出现了AE,既便已报告的AE病例,其在严重性、新颖性及暴露特征等方面也很可能并不能代表整个病人群体的真实情况,因此,对AE漏报情况及其多相性进行定量评估是必要的. In pharmacovigillance efforts, the number of missed reports of Adverse Events (AE) is often unclear, and it is often not clear how many patients actually have AE, even if the reported cases of AE have serious effects on severity , Novelty and exposure characteristics are also likely to not represent the real situation of the entire patient population, therefore, it is necessary to quantitatively evaluate the omission of AE and its heterogeneity.